MNG1065
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.338
- G2M_CHECKPOINT+0.229
- E2F_TARGETS+0.191
- INTERFERON_ALPHA_RESPONSE+0.176
- PROTEIN_SECRETION+0.173
- INTERFERON_GAMMA_RESPONSE+0.127
- IL6_JAK_STAT3_SIGNALING+0.113
- DNA_REPAIR+0.108
- MITOTIC_SPINDLE+0.108
- MTORC1_SIGNALING+0.079
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.394
- ANGIOGENESIS-0.319
- ESTROGEN_RESPONSE_EARLY-0.310
- ESTROGEN_RESPONSE_LATE-0.303
- MYOGENESIS-0.253
- UV_RESPONSE_DN-0.245
- APICAL_JUNCTION-0.244
- ADIPOGENESIS-0.206
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.195
- KRAS_SIGNALING_UP-0.186
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0122212 | — | — | 0.741 |
| 2 | SRR15030894 | — | — | 0.712 |
| 3 | MNG823 | — | — | 0.705 |
| 4 | SRR1313128 | — | D | 0.702 |
| 5 | 87dc0bab-b318-47ec-a9a3-819a7388e731 | — | — | 0.696 |
| 6 | AUR-AE6Y-TTP1-A-1-0-R-A741-41 | — | D | 0.690 |
| 7 | 1b0a23c2-785d-4a14-b673-86c97ceff401 | — | — | 0.680 |
| 8 | TCGA-55-A4DF-01A-11R-A24H-07 | — | cohortA3 | 0.679 |
| 9 | SRR2016974 | — | — | 0.673 |
| 10 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.672 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.338 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.229 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.191 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.176 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.173 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.127 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.113 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.108 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.108 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.079 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.073 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.059 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.041 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.033 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.031 | Inavolisib | — uncovered |